Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 290 SEK -0.21% Market Closed
Market Cap: 99.8B SEK
Have any thoughts about
Swedish Orphan Biovitrum AB (publ)?
Write Note

Swedish Orphan Biovitrum AB (publ)
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Swedish Orphan Biovitrum AB (publ)
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Intangible Assets
kr48.1B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
34%
Biogaia AB
STO:BIOG B
Intangible Assets
kr46.2m
CAGR 3-Years
-3%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Intangible Assets
kr14.2m
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Intangible Assets
kr4.3B
CAGR 3-Years
152%
CAGR 5-Years
63%
CAGR 10-Years
74%
Probi AB
STO:PROB
Intangible Assets
kr340.4m
CAGR 3-Years
-4%
CAGR 5-Years
-7%
CAGR 10-Years
28%
BioArctic AB
STO:BIOA B
Intangible Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Swedish Orphan Biovitrum AB (publ)
Glance View

Market Cap
99.6B SEK
Industry
Biotechnology

Swedish Orphan Biovitrum AB (publ), often referred to as Sobi, is a biopharmaceutical company that has carved a niche in the development and commercialization of innovative treatments for rare diseases, primarily focusing on hematology, immunology, and specialty care. Founded in 2001 and headquartered in Stockholm, Sobi has garnered a reputation for its commitment to improving the lives of patients with complex medical conditions. The company's portfolio includes several key products that address unmet medical needs, particularly in areas such as hemophilia and other inherited disorders. Through strategic partnerships and acquisitions, Sobi has expanded its capabilities, bolstering its research and development pipeline while strengthening its market presence across Europe, North America, and beyond. As an investor, Sobi presents a compelling opportunity in the growing field of rare diseases, bolstered by a robust regulatory framework that often allows for expedited approval processes for groundbreaking therapies. The company’s focus on precision medicine and its dedication to patient-centric care position it well in an industry characterized by high demand and limited competition. With a solid financial foundation and a proactive approach to innovation, Sobi is poised to capture significant market share in a rapidly evolving landscape. Furthermore, with its strategic initiatives in expanding global reach and investing in next-generation therapies, Sobi exemplifies the principles of value investing by aligning long-term growth potential with the increasing need for specialized medical treatments.

SOBI Intrinsic Value
368.27 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Swedish Orphan Biovitrum AB (publ)'s Intangible Assets?
Intangible Assets
48.1B SEK

Based on the financial report for Sep 30, 2024, Swedish Orphan Biovitrum AB (publ)'s Intangible Assets amounts to 48.1B SEK.

What is Swedish Orphan Biovitrum AB (publ)'s Intangible Assets growth rate?
Intangible Assets CAGR 10Y
34%

Over the last year, the Intangible Assets growth was -8%. The average annual Intangible Assets growth rates for Swedish Orphan Biovitrum AB (publ) have been 15% over the past three years , 15% over the past five years , and 34% over the past ten years .

Back to Top